Health News

An HIV drug that redirects immune cell traffic appears to significantly reduce the dangerous complication graft-versus-host disease (GvHD) in blood cancer patients following allogeneic stem cell transplantation (ASCT), according to new research from the Perelman School of Medicine at the University of Pennsylvania that will be presented today at the 53rd American Society of Hematology Annual Meeting.

Read more

Filed under: Pharmacy News
Tags: cancer, Drug, HIV, medicine, Pharmacy

Related posts

• Æterna Zentaris Zentaris requests EMA Scientific Advice for Phase 3 program with perifosine (0)
  Æterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that it has requested Scientific Advice from the European Medicines Agency (EMA) to assure the acceptability of the recently initiated Phase 3 programs for the development of its lead anticancer compound, perifosine, in its two lead indications, multiple myeloma [...]
  
  
• When To Administer Food And Drugs Together (0)
  A regulatory bias against taking oral anti-cancer medications with food places many patients at increased risk for an overdose and forces them to "flush costly medicines down the toilet," argues Mark Ratain, MD, an authority on cancer-drug dosing. In a commentary published early online Sept. 19 in the Journal of Clinical Oncology, Ratain, the Leon [...]
  
  
• U-M scientists identify new reservoir for hidden HIV-infected cells that can serve as factory for new infections (0)
  University of Michigan scientists have identified a new reservoir for hidden HIV-infected cells that can serve as a factory for new infections. The findings, which appear online March 7 in Nature Medicine, indicate a new target for curing the disease so those infected with the virus may someday no longer rely on AIDS drugs for [...]
  
  
• Tibotec submits MAA for investigational HIV drug TMC278 to European Medicines Agency (0)
  Tibotec Pharmaceuticals today announced its submission of a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for TMC278 (rilpivirine, as hydrochloride), an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of HIV. The proposed indication would make TMC278 available for once-daily use with other antiretroviral agents in treatment-naive HIV-1-infected adults. Read more [tags] Pharmacy [...]
  
  
• Supply of childhood leukemia drug nearly exhausted (0)
  A medicine to treat children's leukemia is in such short supply that hospitals may run out within weeks; meanwhile, families of people with Alzheimer's disease are clamoring to use a skin-cancer drug after a promising study in mice. Read more [tags] Pharmacy News [/tags]